Talk:4C-D

From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 4C-D
4C-D
Chemical Nomenclature
Common names 4C-D, ARIADNE, dimoxamine, α-ethyl-2C-D, α-ethyl-DOM, BL-3912
Substitutive name 4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine
Systematic name 1-(2,5-Dimethoxy-4-methylphenyl)butan-2-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenisobutylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 mg
Light 5 - 30 mg
Common 30 - 60 mg
Strong 60 - 100 mg
Heavy 100 mg +
Duration
Total 3 - 10 hours
Onset 15 - 45 minutes
Come up 20 - 40 minutes
Peak 1.5 - 3.5 hours
Offset 0.5 - 4 hours
After effects 1 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine (also known as ARIADNE, dimoxamine, BL-3912 and more commonly as 4C-D) is a synthetic psychedelic that produces a mixture of psychedelic, entactogenic and stimulant effects when administered.

4C-D was first synthesized by Alexander Shulgin and documented in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved").[1] Shulgin has researched dosages up to 32 milligrams, although anecdotal reports suggest that the dosage range for 4C-D is generally higher than what Shulgin documented. Shulgin describes 4C-D as not a true psychedelic and it possessing anti-depressant effects. It has been researched as a potential therapeutic agent for depression and loss of motivation due to its mood-lifting effects.[citation needed]

4C-D has been scarcely distributed as a gray area research chemical by online vendors. Many anecdotal reports suggest that the psychedelic effects begin to unfold at the higher dose range. The dosage levels of 4C-D are therefore not fully clear and one should start at a lower dose when researching this compound. It is highly advised to use harm reduction practices if using this substance.

History and culture

4C-D was once patented as a therapeutic aid in elderly people for restoring motivation under the name Dimoxamine.[citation needed]

Chemistry

Generic structure of a phenethylamine molecule

4C-D, or 4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine, is a substituted phenylisobutylamine featuring a phenyl ring bound to an sec-butylamino chain. 4C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring.

4C-D belongs is an alpha-ethyl substituted phenethylamine and can be considered the alpha-ethyl analog of 2C-D and DOM.

Pharmacology

Further information: Serotonergic psychedelic

4C-D's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

In a forum thread,[2] users have proposed that 4C-D may act as a MAOI, based on structural similarities to 5-MeO-7-Me-AET or 7-Me-AET, which has been shown to act as a strong MAOI and serotonin releasing agent. There is no evidence to support this claim that 4C-D may share these properties as well but it should be taken into consideration when choosing to combine this substance with other monoaminergics.

Subjective effects

The head space of 4C-D is relatively mild at lower dosages and it has been noted for its unusual mood-lifting and motivational effects.

Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Multi-sensory effects
Gears.svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4C-D is a research chemical with very little history of human usage.

Anecdotal evidence from those within the community who have tried 4C-D suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

4C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 4C-D is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4C-D presents cross-tolerance with all psychedelics, meaning that after the consumption of 4C-D all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Lithium - Lithium is commonly prescribed in the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
  • Stimulants (Amphetamine, cocaine, methylphenidate, ...) - Stimulants affect many parts of the brain and alter dopaminergic function. Combined with psychedelics, stimulation can turn into severe anxiety, panic, thought loops, and paranoia. This interaction may result in an elevated risk of mania and psychosis.[citation needed]
  • Tramadol - Tramadol lowers the seizure threshold[3] and psychedelics may act as triggers for seizures in susceptible individuals.[citation needed]

Legal status

  • Germany: 4C-D is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016.[4][5] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[6]
  • Switzerland: 4C-D can be considered a controlled substance as a defined derivative of Phenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.[7]
  • United Kingdom: 4C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[8]
  • United States: 4C-D is technically not scheduled in the United States, but could be considered an analogue of 2C-D or DOMand may therefore be considered a Schedule I drug under the Federal Analogue Act.[citation needed]

See also

External links

Forums

References

  1. https://erowid.org/library/books_online/pihkal/pihkal008.shtml
  2. https://www.bluelight.org/xf/threads/4c-d-ariadne.859113/
  3. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  4. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019. 
  5. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  6. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  7. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  8. United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made